Literature DB >> 3055192

Stimulation of secretory antibody following oral administration of antigen.

K C Bergmann1, R H Waldman.   

Abstract

IgA antibodies produced by plasma cells in secretory tissues associated with mucosal surfaces represent a major host defense against infectious agents. Precursors of these IgA-producing cells originate in gut-associated lymphoid tissue and, to a lesser extent, in bronchial-associated lymphoid tissue and migrate via the blood not only to gut but also to other mucosal tissues, forming a common mucosal immune system. Oral administration of antigen leads to priming of precursor cells in the gut and subsequent occurrence of specific secretory IgA (S-IgA) antibody in saliva, milk, tears, and the respiratory and genital tracts. On the basis of a review of the world literature, it has been concluded that oral live vaccines elicit higher antibody titers in remote-site secretions and in serum than do oral killed vaccines, which usually stimulate only relatively low levels of local secretory antibody. Oral immunization induces S-IgA in children and adults (including the elderly) without detectable adverse effects. Despite a number of remaining questions, oral immunization against extraintestinal infections is a promising area for future clinical studies.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3055192     DOI: 10.1093/clinids/10.5.939

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  14 in total

1.  Effects of a bacterial extract on local immunity of the lung in patients with chronic bronchitis.

Authors:  B Emmerich; H P Emslander; D Milatovic; M Hallek; K Pachmann
Journal:  Lung       Date:  1990       Impact factor: 2.584

2.  Rotavirus virus-like particles administered mucosally induce protective immunity.

Authors:  C M O'Neal; S E Crawford; M K Estes; M E Conner
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 3.  Oral delivery of vaccines. Formulation and clinical pharmacokinetic considerations.

Authors:  D T O'Hagan
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

4.  Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres.

Authors:  K Allaoui-Attarki; S Pecquet; E Fattal; S Trollé; E Chachaty; P Couvreur; A Andremont
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

5.  Mucosal and systemic immune responses in BALB/c mice to Bacteroides gingivalis fimbriae administered orally.

Authors:  T Ogawa; H Shimauchi; S Hamada
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

Review 6.  Vaccination strategies for mucosal immune responses.

Authors:  P L Ogra; H Faden; R C Welliver
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

7.  Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice.

Authors:  J M Ball; M E Hardy; R L Atmar; M E Conner; M K Estes
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

8.  Epidemiology of the M-component immunoglobulin types of multiple myeloma.

Authors:  L J Herrinton; P A Demers; T D Koepsell; N S Weiss; J R Daling; J W Taylor; J L Lyon; G M Swanson; R S Greenberg
Journal:  Cancer Causes Control       Date:  1993-03       Impact factor: 2.506

9.  Enteric immunization of mice against influenza with recombinant vaccinia.

Authors:  C A Meitin; B S Bender; P A Small
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

10.  Mucosal immune response to RDEC-1 infection: study of lamina propria antibody-producing cells and biliary antibody.

Authors:  C E McQueen; E C Boedeker; M Le; Y Hamada; W R Brown
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.